FDA Adverse Event Rating Scale Could Follow NCI Model, Consultant Says
Executive Summary
The National Cancer Institute Common Toxicity Criteria could be a model for a standardized adverse event severity scale, International Pharmaceutical Consultants President Herbert Swarz, MD, suggested during a May 22 FDA hearing on risk management
You may also be interested in...
Pharmacy Risk Management Wish-List: “Opt-In” Feature, “Core Protocols”
Limited distribution programs for pharmaceuticals should include an "opt-in" feature to allow participation of any qualified pharmacy, the American Pharmaceutical Association told FDA during a May 22 hearing on risk management
FDA Proposed Rule Will Require MedDRA for Postmarketing AE Reporting
FDA's Suspected Adverse Drug Reaction proposed rule will seek to require the use of MedDRA terminology in submissions of postmarketing adverse event reports, the agency told a Drug Information Association workshop on MedDRA implementation Oct. 30 in Washington, D.C.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011